drugset / Trial / NCT06464614
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
Phase 2
Not yet recruiting
54 enrolled
The First Affiliated Hospital of Henan University of Science and Technology
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic disease)，and to evaluate the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (without symptomatic dysphagia or oligometastatic disease).
Timeline
- Start
- 2024-07-15
- Primary completion
- 2025-08-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Background | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Background | Ilinotecan | Unknown | 125 mg/m2 | Intravenous |
| Background | Nab-paclitaxel | Small molecule | 100 mg | Intravenous |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |